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Naphthalene-sulfonateNoroviruses are members of the Caliciviridae family of positive sense RNA viruses. In humans Noroviruses
cause rapid onset diarrhea and vomiting. Currently Norovirus infection is responsible for 21 million gas-
troenteritis yearly cases in the USA. Nevertheless, despite the obvious public health and socio-economic
relevance, no effective vaccines/antivirals are yet available to treat Norovirus infection.
Since the activity of RNA-dependent RNA polymerase (RdRp) plays a key role in genome replication and
in the synthesis/ampliﬁcation of subgenomic RNA, the enzyme is considered a promising target for anti-
viral drug development. In this context, following the identiﬁcation of suramin and NF023 as Norovirus
RdRp inhibitors, we analyzed the potential inhibitory role of naphthalene di-sulfonate (NAF2), a fragment
derived from these two molecules. Although NAF2, tested in enzymatic polymerase inhibition assays, dis-
played low activity against RdRp (IC50 = 14 lM), the crystal structure of human Norovirus RdRp revealed
a thumb domain NAF2 binding site that differs from that characterized for NF023/suramin. To further
map the new potential inhibitory site, we focused on the structurally related molecule pyridoxal-50-phos-
phate-6-(20-naphthylazo-60-nitro-40 ,80-disulfonate) tetrasodium salt (PPNDS). PPNDS displayed below-
micromolar inhibitory activity versus human Norovirus RdRp (IC50 = 0.45 lM), similarly to suramin and
NF023. Inspection of the crystal structure of the RdRp/PPNDS complex showed that the inhibitor bound
to the NAF2 thumb domain site, highlighting the relevance of such new binding site for exploiting Noro-
virus RdRp inhibitors.
 2013 Elsevier B.V. All rights reserved.1. Introduction
Noroviruses (NVs) are members of the Caliciviridae family of po-
sitive sense RNA viruses (Fauquet and Fargette, 2005; Green, 2007;
Green et al., 2000; Mayo, 2002). Norovirus-linked gastroenteritis is
estimated to affect 21 million people annually in the United
States, being responsible for up to 200,000 deaths per year in
developing countries (Patel et al., 2008). The disease is usually
acute and self-limiting, but in immunocompromised adults it canbecome chronic and persist for weeks–years (Bok and Green,
2012).
The NV genome (7.7 kb) contains three open reading frames
(ORF1-3) of single stranded RNA. ORF1 is translated into a large
polyprotein precursor, cleaved into six non-structural proteins
(NS1–2, NS3, NS4, NS5, NS6 and NS7) by the viral protease
(NS6); ORF2 and ORF3 encode for the capsid proteins VP1 and
VP2, respectively (Clarke and Lambden, 2000). The structural and
non-structural viral proteins that orchestrate the viral replicative
machinery are potentially vulnerable targets for ‘‘attack’’ by proper
ligands interfering with their functionality (Rohayem et al., 2010).
The virus-speciﬁc nature of such targets, and their indispensable
functions, provide the potential for limiting negative side effects
of antiviral drugs on the physiologic host-cell processes.
In this context, we formerly identiﬁed suramin and the analo-
gous compound NF023 as human and murine NV NS7 RNA-depen-
dent RNA-polymerase (hNV- and mNV-RdRp, respectively)
inhibitors (Mastrangelo et al., 2012). Our crystallographic analyses
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to a common site, close to the enzyme catalytic center. Suramin
and derivatives display poor membrane permeability (Beindl
et al., 1996; Charlton et al., 1996; Klinger et al., 2001) due to the
negative charges of their sulfonate groups, and would require
chemical optimization to improve their drug-likeness. On the other
hand, the suramin/NF023 binding site is located along the access
pathway of incoming nucleoside triphosphates (NTPs) and is lined,
in its central region, with lysine and arginine residues endowed
with highly mobile side chains. Such conformational ﬂexibility of
the targeted binding site adds substantial complexity to the struc-
ture-based inhibitor optimization process. On such bases, we set
out to investigate a fragment of the two mentioned inhibitors that,
according to our crystal structures, mapped to the less ﬂexible re-
gion (i.e. inner in the enzyme active site) of the suramin/NF023
binding site, likely representing their most inhibitory-active por-
tion. We thus focused on naphthalene-1,5-disulphonic acid
(NAF2; Fig. 1a) as a fragment of both suramin and NF023 ‘inhibi-
tory heads’, applying a sort of reverse fragment screening
approach.
NAF2 was initially tested in enzymatic assays for inhibition of
hNV-RdRp, showing modest activity (IC50 = 14 lM). Unexpectedly,
however, the crystal structure of the hNV-RdRp/NAF2 complex
showed that, besides the site previously characterized in the sura-
min/NF023 complexes, the compound bound also to a new thumb
domain site, located in a cleft along the newly synthesized RNA
exit path. Accordingly, the two NAF2 binding sites identiﬁed were
named A-site (‘old’ site, common with suramin/NF023) and B-site
(‘new’ site). In order to further characterize the B-site in view of its
exploitation for inhibitor design, we then selected the NAF2 analog
pyridoxal-50-phosphate-6-(20-naphthylazo-60-nitro-40,80-disulfo-
nate) tetrasodium salt (PPNDS, Fig. 1b), which our previous dock-
ing searches showed to potentially map to a region close to the
B-site (Mastrangelo et al., 2012). PPNDS proved able to inhibit
hNV-RdRp activity with an IC50 value in the sub-micromolar range
(IC50 = 0.45 lM). Moreover, the crystal structure of the hNV-RdRp/
PPNDS complex showed that the inhibitor indeed bound to the B-
site previously mapped by NAF2. Our ﬁndings highlight a new
RdRp inhibitory sub-site, and suggest that structure-based optimi-
zation of PPNDS may provide analogs with enhanced drug-like-
ness, shedding new light on the path towards anti-Norovirus
drugs.2. Materials and methods
2.1. Chemicals
For the RdRp inhibition assays poly(C) and the NAF2 compound
were purchased from Sigma–Aldrich, while PPNDS was from Santa
Cruz Biotechnology. The compounds were dissolved at 100 mM in
H2O and stored at –20 C.Fig. 1. Chemical structure of NAF2 (a) and PPNDS (b).2.2. Expression and puriﬁcation of the hNV-RdRp
hNV-RdRp was expressed in Escherichia coli and puriﬁed as pre-
viously described (Fullerton et al., 2007). The protein was dialyzed
against buffer A (25 mM Tris/HCl, pH 7.4, 1 mM DTT, 100 mMNaCl,
1 mM EDTA) and concentrated to 9 mg/ml. Protein concentration
was determined with the BCA Protein assay kit (Pierce) based on
the Biuret reaction.
2.3. hNV-RdRp inhibition assays
In vitro RNA synthesis assays were performed as described
(Mastrangelo et al., 2012). In brief the reaction mixture contained
20 mM Tris/HCl (pH 7.5), 1 mM DTT, 25 mM NaCl, 5 mM MgCl2,
0.3 mM MnCl2, 2 U RiboLock Ribonuclease inhibitor, PicoGreen
Quantitation Reagent, and as substrates poly(C) template annealed
with oligo(G)12 primer (62.5 nM ﬁnal concentration), and 100 lM
GTP. Before starting the reaction, 1 ll of the protein was incubated
for 5 min in the presence of 1 ll of water or 1 ll of one inhibitor
solution at the required concentration. The reaction was started
by the addition of the reaction mixture to the incubated protein (ﬁ-
nal protein concentration 255 nM; inhibitor concentration from 0
to 20 lM for NAF2, and from 0 to 10 lM for PPNDS) up to a total
volume of 200 ll. The reactions were followed for 10 min at
30 C recording (every 30 s) the ﬂuorescence signals of the samples
(in a Varian Cary Eclipse Fluorescence Spectrophotometer) arising
from the interaction of the PicoGreen dye with the growing dsRNA.
Protein activity was evaluated subtracting the slope of the linearly
growing ﬂuorescence from that of the same reaction mix win the
absence of the enzyme. The results of three independent experi-
ments were averaged. A plot of activity versus inhibitor concentra-
tion was used to estimate the IC50 values for each inhibitor
(Table 1; Fig. S1) using the program GraFit (Erithacus software)
or QtiPlot, using the four parameter equation:
A ¼ mþ ðM mÞ 1
1þ ½IIC50
 n
where A = activity, M = maximum activity, m = minimum activity,
[I]=inhibitor concentration, n = Hill coefﬁcient (Prinz, 2010).
Independently, kinetic experiments were performed in order to
determine the PPNDS hNV RdRp inhibition mechanism relative to
the poly(C)/oligo(G)12 substrate. Brieﬂy, to explore the inhibition
mode, we performed standard enzymatic reactions for which the
poly(C)/oligo(G)12 concentration was varied (from 3.9 to 125 nM),
at 100 lM GTP constant concentration, applying increasing
amounts of the inhibitor (from 0 to 1 lM). The assays were per-
formed using a TECAN Inﬁnite 200 PRO microplate reader; the re-
sults were analyzed through Lineweaver–Burk plots (1/V versus 1/
[S]) at varying PPNDS concentrations.
2.4. Biophysical characterization of the hNV-RdRp/inhibitor interaction
Thermoﬂuorimetric (Thermal shift) assays for the evaluation of
the hNV-RdRp melting temperature (Tm) in the absence/presence
of the inhibitors were conducted in a MiniOpticon Real Time PCR
Detection System (Bio-Rad), using the ﬂuorescent dye Sypro Or-
ange. 4 ll aliquots of hNV-RdRp solution (ﬁnal protein concentra-Table 1
IC50 values of the different compounds against hNV-RdRp.
Cpd hNV-RdRp IC50 (lM)
Suramin 0.24 ± 0.08
NAF2 14.0 ± 1.0
PPNDS 0.45 ± 0.09
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3.5 ll of Sypro orange (Sigma) diluted 60, and PPNDS (5 or
50 lM), or 700 lMNAF2. In control samples the inhibitor solutions
were replaced by water. The sample plates were heated from 20 to
90 C, with a heating rate of 0.2 C/min. Fluorescence intensities
were measured within excitation/emission ranges of 470–505 nm
and 540–700 nm, respectively.2.5. Crystallization of the hNV-RdRp in presence of NAF2 and PPNDS
Sitting drop crystallization experiments for hNV-RdRp (11 mg/
ml stock enzyme concentration) were assembled using an Oryx-8
crystallization robot (Douglas Instruments, East Garston, UK), from
a 50%, 67%, 80% mixture of the protein with the reservoir solution
(ﬁnal drop volume 0.3 ll). Crystals grew in about 4 weeks, at 20 C,
in 1.2 M Na citrate, 100 mM Na cacodylate, pH 6.2, NaCl 125 mM.
Before X-ray data collection, crystals were soaked in a cryoprotec-
tant solution (1.4 M Na citrate, 100 mM Na cacodylate pH 6.2, and
25% glycerol) containing 30 mM NAF2, for 24 h, or containing
5 mM of PPNDS, 62.5 nM dsRNA (poly(C)/oligo(G)12) and 100 lM
GTP, for 36 h. The soaked crystals were then ﬂash-cooled in liquid
nitrogen. The hNV-RdRp/NAF2 crystals diffracted to a maximum
resolution of 2.04 Å at the Elettra Synchrotron source (Trieste,
Italy), beam line XRD1. The hNV-RdRp/PPNDS crystals diffracted
to a maximum resolution of 2.6 Å at the ESRF Synchrotron facility
(Grenoble, France), beam line ID29.
hNV-RdRp/NAF2 X-ray diffraction data were indexed using
MOSFLM (Read et al., 2007), and intensities were merged using
SCALA (Evans, 2006). hNV-RdRp/PPNDS X-ray diffraction data were
indexed and scaled using XDS (Kabsch, 2010). The hNV-RdRp crys-
tals grown in the presence both of NAF2 or PPNDS display closely
similar unit cells and belong to the orthorhombic space group I222;
data collection statistics are reported in Table 2.Table 2
X-ray data-collection and reﬁnement statistics for hNV-RdRp/NAF2 and for hNV-
RdRp/PPNDS.
Protein hNV-RdRp/NAF2 hNV-RdRp/PPNDS
Soaked compound NAF2, 30 mM PPNDS, 5 mM
Ligand site(s) present A-site, B-site B-site
Beam line & wavelength (Å) ELETTRA XRD1
1.000
ESRF ID29 1.072
Space group I222 I222
Unit-cell parameters (Å) a = 86.6; b = 111.8;
c = 121.4
a = 85.8; b = 116.1;
c = 122.1
Molecules in a.u. 1 1
Resolution (Å) 45.4–2.04 38.4–2.6
Mosaicity () 0.6 0.4
Measured reﬂections 138,897 (20,166)a 87,361 (6,478)c
Unique reﬂections 37,405 (5,330) 19,046 (1,383)
Completeness (%) 98.7 (97.7) 99.6 (99.7)
Redundancy 3.7 (3.8) 4.6 (4.7)
Rmergea (%) 10.3 (41.7) 10.4 (73.8)
Average I/r (I) 9.1 (2.7) 12.1 (1.9)
Rfactorb/R freec (%) 17.0/22.3 22.0/28.5
r.m.s. Bonds (Å) 0.010 0.008
r.m.s. Angles () 1.37 1.18
Average protein B fac. (Å2) 22.4 57.5
Average ligand B fac. (Å2) B-site = 20.9
A-site = 32.2
B-site = 85.2
Residues in most favored
regions (%)
93.4 91.8
Residues in additionally
allowed regions (%)
6.6 8.2
PDB-ID 4LQ9 4LQ3
Values in parentheses are for the highest resolution shell: a(2.15–2.04); b(2.66–
2.60).
a Rmerge =R|I(I)|/RI  100, where I is intensity of a reﬂection and (I) is its
average intensity.
b Rfactor = R|FoFc|/R|Fo|  100.
c Rfree is calculated on 5% randomly selected reﬂections, for cross-validation.2.6. Structure determination and reﬁnement
The three-dimensional structures of hNV-RdRp in the com-
plexes with NAF2 and PPNDS were solved by the Molecular
Replacement method using the program MOLREP (Vagin and
Teplyakov, 1997) and a search model based on the structure of
the hNV-RdRp from strain Hu/NLV/Dresden174/1997/GE (PDB-id
2B43). The single molecule present in the crystal asymmetric unit
was subjected to rigid-body reﬁnement, and subsequently to con-
strained reﬁned using REFMAC5 (Steiner et al., 2003). A random set
comprising 5% of the data was omitted from reﬁnement for R-free
calculation. Manual rebuilding with COOT (Emsley et al., 2010);
additional reﬁnement with BUSTER (Smart et al., 2012) and REF-
MAC5, were subsequently performed, as needed. Reﬁnement sta-
tistics as well as stereochemical quality assessment of the 3D
structures are summarized in Table 2. Atomic coordinates and
structure factors for hNV-RdRp in complex with NAF2 and PPNDS
have been deposited with the PDB (Berman et al., 2000) with
accession codes 4LQ9 and 4LQ3, respectively.
3. Results
3.1. In vitro inhibition of hNV-RdRp
In vitro RNA synthesis assays were performed using annealed
poly(C)–oligo(G)12 (62.5 nM ﬁnal concentration) and GTP
(100 lM ﬁnal concentration), as polymerase substrates, and
255 nM RdRp, following procedures previously described (Mastr-
angelo et al., 2012). Under these experimental conditions, NAF2
inhibited hNV-RdRp activity with IC50 = 14 lM whereas PPNDS
inhibited the enzyme with an IC50 value of about 0.45 lM (Table 1;
Fig. S1). Furthermore, analyzing the dose–response curves for
NAF2, it is evident that the number of bound inhibitor molecules
is higher than 1 (Prinz, 2010). As described in the next paragraph,
such value is in agreement with the crystal structure data, where
we observed two ligand binding sites (see below).
We also analyzed the kinetic mechanism of hNV-RdRp inhibi-
tion by PPNDS (Fig. 2). The Lineweaver–Burk plots highlighted a
non-competitive inhibition mechanism with respect to the
poly(C)/oligo(G)12 substrate, with a Ki value of 0.52 ± 0.05 lM,
indicating that the inhibitor is able to bind to the free enzyme as
well as to the enzyme–substrate complex.
In order to verify whether the selected compounds might in-
duce some form of destabilization/denaturation of the enzyme,
generally reﬂected by a variation of the protein Tm, we performed
thermoﬂuorimetric assays. The acquired data showed that hNV-
RdRp displays the same Tm in the absence (Tm = 36.9 ± 0.5 C) or
in the presence of NAF2 (0.7 mM; Tm = 37.5 ± 0.4 C). The thermo-
ﬂuorimetric signal recorded in the presence of PPNDS is markedly
reduced when the inhibitor concentration is raised, since the red
colored inhibitor molecule absorbs part of the incident radiation
(in the 470–505 nm range). We were however able to test the ef-
fects on Tm at two PPNDS concentrations (5 and 50 lM), resulting
in Tm values of 37.0 ± 0.5 and 41.0 ± 2.0, respectively (Fig. S2a and
b). Despite the low ﬂuorescence signal recorded in the presence of
50 lM PPNDS, the slight Tm increase observed would imply some
protein stabilization induced by the bound inhibitor. All the ther-
moﬂuorimetric results prove that the hNV-RdRp inhibition is not
due to inhibitor-linked adverse effects on enzyme stability/
denaturation.
3.2. Crystal structures of hNV-RdRp with NAF2
3.2.1. Inhibitor binding to the B-site
The analysis of NAF2 binding to the RdRp domain was
addressed through X-ray crystallography. To this purpose,
Fig. 2. (a) Reaction velocity plot as a function of the RNA concentration, s in
absence of the inhibitor, d in presence of 0.45 lM of PPNDS and h in presence of
1 lM of PPNDS. (b) Lineweaver–Burk double reciprocal plot for the non competitive
inhibition mechanism of hNV RdRp activity by PPNDS, relative to RNA substrate.
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of NAF2 (see Section 2for details). The hNV-RdRp crystals were
soaked in 30 mM NAF2 before cryo-cooling, The crystal (belonging
to the orthorhombic space group I222, with one molecule per
asymmetric unit) diffracted to a maximum resolution of 2.04 Å,Fig. 3. (a) Crystal structure of hNV-RdRp bound to two NAF2 molecules in the A-site an
thumb (red), ﬁngers (yellow) and palm (green). The picture on the right is rotated by 90 d
the B-site (b) and A-site (c); transparent surface colored by electrostatic potential (progra
labeled. Figures created using PyMol (http://www.pymol.org). (For interpretation of the
this article.)and the structure was reﬁned to a ﬁnal crystallographic R-factor
of 17.0% and R-free of 22.3% (Table 2). The ﬁrst reﬁnement cycles
showed residual electron density compatible with a NAF2 mole-
cule located in a positively charged cleft within the thumb domain
(Fig. 3a and b), built by an a-b-loop-a motif; inspection of the en-
zyme structure conﬁrms that this site (hereafter, the B-site) is dif-
ferent from the binding site where suramin and NF023 inhibitors
were located (hereafter, the A-site). In the B-site, the negative
charges of NAF2 sulfonates are balanced by Arg419 and Arg436;
the naphthalene ring is sandwiched between Gln414 and Gln439
(forming an intertwined hydrogen bond network together with
Asn505), on one side, and Phe28 and Arg419, on the other
(Fig. 3b). Additional polar interactions involve the side chains of
Asn505 and Thr418 and the main chain nitrogen of Arg419. Inspec-
tion of the hNV-RdRp/NAF2 crystal structure in comparison to the
enzyme 3D structure in the absence of inhibitors (pdb-id: 2B43,
r.m.s.d. 0.70 Å, over 499 Ca pairs) shows that, upon NAF2 binding,
the protein undergoes only slight structural rearrangements at a
few residues, and at the last two C-terminal residues, Asn505
and Glu506, visible in the electron density.3.2.2. Inhibitor binding to the A-site
Further inspection of difference Fourier maps revealed residual
electron density compatible with one NAF2 molecule in the A-site
(Fig. 3a and c), i.e. at a location very close to the site occupied by
the naphthalene-sulfonate moiety of NF023/suramin, in the ﬁngers
domain (Fig. 3c; Mastrangelo et al., 2012). Lys171, Lys174, Lys180
and Arg182 stabilize the inhibitor negative charges; the sulfonate
groups establish H-bonds with Gln66 and the main chain N atom
of Lys171. Additionally, the naphthalene ring makes p-cation inter-
actions with Lys174 and Arg182 (Fig. 3c).3.3. Crystal structure of hNV-RdRp bound to PPNDS
In a previous virtual screening search targeting a wide region
around the hNV-RdRp active site, we identiﬁed PPNDS, a com-
pound hosting a naphthalene disulfonate moiety, among other po-
tential NV-RdRp inhibitors (Mastrangelo et al. 2012). Analysis of
the simulated structure showed that PPNDS would locate in ad B-site; the overall structure of hNV-RdRp in cartoon: N-terminal domain (blue),
egree around the vertical axis. (b and c) Details of the hNV-RdRp/NAF2 interaction in
m APBS2; (Baker et al., 2001)); amino acids involved in the interaction with NAF2 are
references to color in this ﬁgure legend, the reader is referred to the web version of
D. Tarantino et al. / Antiviral Research 102 (2014) 23–28 27region close to the B-site described above. Therefore, for the pres-
ent study, PPNDS was selected as a commercially available com-
pound potentially useful to further characterize structural
features of the newly identiﬁed B-site. Notably, we succeeded in
obtaining crystals of hNV-RdRp bound to PPNDS only after soaking
the protein with the inhibitor in the presence of dsRNA and GTP
(see Section 2.5 for details). This suggests that inhibitor binding
to the protein requires local structural changes related to events
in the catalytic cycle. The protein crystal structure was reﬁned to
a ﬁnal crystallographic R-factor of 22.0%, and R-free of 28.5%, for
the 2.6 Å resolution data set (Table 2). As predicted by the docking
study, PPNDS binds only to the B-site (Fig. 4, Fig. S3a and b). The
overall structure of the whole enzyme bound to PPNDS appears
slightly more compact relative to that of the inhibitor-free protein
(pdb-id 1SH0; r.m.s.d. 1.01 Å, over 484 Ca pairs (Ng et al., 2004)).
Such overall effect is related to a small displacement of both the
ﬁngers and the thumb domains toward the active site, as in a clos-
ing hand, and is likely due to the interaction of the protein with
dsRNA (Fig. 4a and b). In fact, the crystal structure shows residual
electron density hosted between the ﬁngers and thumb domains
compatible with two or three RNA nucleotides, which have been
only partially modeled in the reﬁned structure, due to electron
density ambiguities. The nucleotides are hosted in a positively
charged region along the exit pathway of the newly formed RNA
chain (Zamyatkin et al., 2008).
The PPNDS molecule can be schematically divided into two
moieties, the naphthalene 60-nitro-40,80-disulfonate and the pyri-
doxal-50-phosphate, linked by the azo bond (Fig. 1b). The nitro
group of the ﬁrst moiety is tightly hosted in a hydrophobic cleft,
between helices a13 and a14 of the thumb domain, lined with
Leu406, Ile411 (a13), Leu443 (a14), Val504 (C-terminal) and with
the aliphatic portion of the side chains of Ser 410 (a13), Gln414
(a13) and Glu446 (a14) (Fig. 4c, Fig. S3b). Both PPNDS sulfonate
groups point toward the solvent; the 80 sulfonate establishes
hydrogen bonds with Gln414 and Gln439, while the 4’ sulfonate
is H-bonded to Ser410 and salt bridges with Arg413 and Arg392
(Fig. 4c). The naphthalene ring is in van der Waals contacts with
Gln414. The PPNDS pyridoxal-50-phosphate group is elongatedFig. 4. (a) Crystal structure of hNV-RdRp bound to PPNDS in cartoon. PPNDS (orange carb
(gray) are shown as sticks. (b) Same as (a) with protein surface colored by electrostatic po
involved in the interaction with PPNDS are labeled. (For interpretation of the references ttoward the ﬁngers domain, stabilizing the conformation of the C-
ter end of hNV-RdRp within the active site cavity (Fig. 4a and c).
In fact, while in the inhibitor-free enzyme the C-ter is modeled
in the electron density up to Glu506–Asp507, when PPNDS is pres-
ent all the C-ter residues can be modeled (Glu510 is in van der
Waals contact with the pyridoxal moiety, and H-bonded to its
phosphate group). Interestingly, the PPNDS phosphate group
points toward the active site region in the palm domain, which is
rich in negatively charged amino acids, partially masked by
Arg182, Arg392 and Mg2+. Finally, the carbonyl group of the pyri-
doxal ring is H-bonded to Glu168. Relative to NAF2, the PPNDS
molecule appears to be shifted toward the palm domain of about
two a helical turns (6–7 Å) along the direction of the antiparallel
helices a13 and a14. Such PPNDS location may be dictated by the
nitro group that cannot be properly hosted in the NAF2 cavity due
to clash with Trp417 main chain (in the a13-b motif of the thumb
domain). Notably, the location of PPNDS at a site different from the
previously identiﬁed A-site is independently assessed by the close
matching of the IC50 values obtained (as described above) for w.t.
hNV-RdRp (Table 1) and for its Y41A mutant, where a key residue
building the A-site is replaced by Ala (IC50 of about 500 ± 50 nM).
In fact, such a mutation was previously shown to affect suramin
and NF023 inhibitory effects on hNV-RdRp (Mastrangelo et al.,
2012).4. Discussion
In a previous work (Mastrangelo et al., 2012) we showed that
suramin and NF023 binding site to mNV-RdRp, and to hNV-RdRp,
as inferred by crystal structures and mutation analysis, is located
along the access pathway of NTPs to the enzyme active center.
Accordingly, such site is lined with positively charged residues
whose conformational ﬂexibility helps promoting the diffusion of
NTPs toward the catalytic site. Such structural features are unlikely
to make this inhibitor binding site an ideal target region for
structure based drug optimization. We therefore decided to ana-
lyze the structural and inhibitory properties of fragments of theon atoms) and a fragment of ssRNA, partially modeled into observed electron density
tential. (c) Details of the local contacts between PPNDS and hNV-RdRp; amino acids
o color in this ﬁgure legend, the reader is referred to the web version of this article.)
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eties, thus selecting the NAF2 compound. Enzymatic assays
showed that the selected fragment of the initial inhibitors still re-
tains marginal inhibitory activity. More importantly, besides the
site previously characterized in the suramin/NF023 complexes
(here identiﬁed as the A-site), such reverse fragment screening
experiments unraveled a novel, unexpected, binding site for
NAF2, located in the RdRp thumb domain (B-site). Interestingly,
the B-site is located in a position that is roughly structurally equiv-
alent to the benzothiadiazine inhibitor binding site in the Hepatitis
C Virus RdRp (Koch and Narjes, 2006; Pfefferkorn et al., 2005).
NAF2 binding to two distinct sites is also suggested by analysis
of the inhibition mechanism which shows a Hill coefﬁcient higher
than 1. In order to further characterize the B-site we selected
PPNDS, a naphthalene sulfonate-based compound that is a potent
and selective P2X1 receptor antagonist (Lambrecht et al., 2000).
We demonstrated that PPNDS is able to inhibit the polymerase
activity (Hill coefﬁcient 1, Fig. S1b) with a potency close to that
observed for suramin or NF023. The crystal structure of the hNV-
RdRp/PPNDS complex shows that the compound is anchored to
the protein mostly through its naphthalene moiety. On the other
hand, the improved inhibitory efﬁcacy is likely dependent on
PPNDS pyridoxal moiety that extends toward the enzyme active
site. Such consideration is in keeping with the fact that: (i) NAF2
does not exert considerable inhibition, and (ii) PPNDS helps ﬁxing
the C-terminal end of the enzyme inside the active site, likely
blocking the access of both the ssRNA template and the NTPs.
The discovery of a new inhibitor binding site, and our analysis of
the PPNDS binding mode to hNV-RdRp, provide new structural
bases for modiﬁcation of PPNDS and/or related compounds, in or-
der to improve its efﬁcacy and drug-likeness.
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